With this aim, we prospectively evaluated myeloidderived suppressor cell frequency and functional activity during immunotherapy for lung cancer. In this patient with stage III nonesmall-cell lung cancer, durvalumab in maintenance promoted a strong reduction in both myeloid-derived suppressor cell1 frequency and activity, as well as in the expression of immunosuppression-associated genes.
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report
BERTELLI, GIACOMO;Trovato, Rosalinda;Ugel, Stefano;Bria, Emilio;Milella, Michele;Bronte, Vincenzo;Pilotto, Sara
2019-01-01
Abstract
With this aim, we prospectively evaluated myeloidderived suppressor cell frequency and functional activity during immunotherapy for lung cancer. In this patient with stage III nonesmall-cell lung cancer, durvalumab in maintenance promoted a strong reduction in both myeloid-derived suppressor cell1 frequency and activity, as well as in the expression of immunosuppression-associated genes.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
